These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8368738)

  • 1. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens.
    Bystryn JC
    Ann N Y Acad Sci; 1993 Aug; 690():190-203. PubMed ID: 8368738
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials with VMO for melanoma.
    Wallack MK; Sivanandham M
    Ann N Y Acad Sci; 1993 Aug; 690():178-89. PubMed ID: 8368736
    [No Abstract]   [Full Text] [Related]  

  • 3. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma.
    Morton DL; Hoon DS; Nizze JA; Foshag LJ; Famatiga E; Wanek LA; Chang C; Irie RF; Gupta RK; Elashoff R
    Ann N Y Acad Sci; 1993 Aug; 690():120-34. PubMed ID: 8368731
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical activity of a polyvalent melanoma antigen vaccine.
    Bystryn JC
    Recent Results Cancer Res; 1995; 139():337-48. PubMed ID: 7597302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of T-cell response with a melanoma cell vaccine expressing specific HLA-A antigens.
    Hoon DS; Morisaki T; Uchiyama A; Hayashi Y; Foshag LJ; Nizze AJ; Morton DL
    Ann N Y Acad Sci; 1993 Aug; 690():343-5. PubMed ID: 8368751
    [No Abstract]   [Full Text] [Related]  

  • 6. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action.
    Mitchell MS; Harel W; Kan-Mitchell J; LeMay LG; Goedegebuure P; Huang XQ; Hofman F; Groshen S
    Ann N Y Acad Sci; 1993 Aug; 690():153-66. PubMed ID: 8368734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
    Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
    Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunological analysis of melanoma-specific antigen].
    Wakabayashi S; Okamoto S
    Nihon Hifuka Gakkai Zasshi; 1985 Oct; 95(11):1145-51. PubMed ID: 3879298
    [No Abstract]   [Full Text] [Related]  

  • 9. Preparation and characterization of a polyvalent human melanoma antigen vaccine.
    Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M
    J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
    Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
    Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and tumor protective activity of B16 melanoma vaccines.
    Johnston D; Bystryn JC
    Mol Biother; 1989; 1(4):218-22. PubMed ID: 2818873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunological analysis of melanoma specific antigen. II. Inhibition of killer T cell activity by anti-melanoma antibody and anti-H-2b antibody].
    Wakabayashi S; Taniguchi M; Tomioka H; Okamoto S
    Nihon Hifuka Gakkai Zasshi; 1984 Feb; 94(2):143-9. PubMed ID: 6610781
    [No Abstract]   [Full Text] [Related]  

  • 13. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
    Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses.
    Niederkorn JY; Streilein JW
    J Immunol; 1983 Dec; 131(6):2670-4. PubMed ID: 6196396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active-specific immunotherapy for melanoma.
    Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
    J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel DNA vaccine constructed by heat shock protein 70 and melanoma antigen-encoding gene 3 against tumorigenesis.
    Qu P; Ma JH; Zhang XM; Huang XJ; Yang XW; Yan-Fang S
    Indian J Exp Biol; 2010 May; 48(5):436-43. PubMed ID: 20795360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in patients with melanoma.
    Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
    Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
    Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
    J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppressed cellular immunity in mice harboring intraocular melanomas.
    Niederkorn JY
    Invest Ophthalmol Vis Sci; 1984 Apr; 25(4):447-54. PubMed ID: 6608506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.